Showing results (2261-2270 of 3,105) with videos related to
Sort By:
Pageof 311
Expert Review of Anticancer Therapy|November 23, 2023
NECTIN-4 targeted theranostics for urothelial cancer: getting ready for primetime?Luca Filippi, Orazio SchillaciExpert Review of Anticancer Therapy|March 4, 2024
Efficacy and safety of neoadjuvant combination immunotherapy in surgically resectable malignant solid tumors: a systematic review and meta-analysisYuqian Feng, Kaibo Guo, Huimin Jin, et al.Expert Review of Anticancer Therapy|March 7, 2024
Positron emission computed tomography targeting urokinase plasminogen activator receptor (uPAR) in cancer: a systematic reviewRiccardo Camedda, Viviana Frantellizzi, Roberta Danieli, et al.Expert Review of Anticancer Therapy|April 10, 2024
Current usage of pembrolizumab in triple negative breast cancer (TNBC)Harriet O'Rourke, Christopher Hart, Richard H De BoerExpert Review of Anticancer Therapy|February 26, 2024
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancerJunping Lei, Jia Fu, Tianyang Wang, et al.Expert Review of Anticancer Therapy|May 30, 2024
Multidisciplinary systemic and local therapies for metastatic renal cell carcinoma: a narrative reviewMartin Zarba, Ryo Fujiwara, Takeshi Yuasa, et al.Expert Review of Anticancer Therapy|May 30, 2024
First-line concomitant EGFR-TKI + chemotherapy versus EGFR-TKI alone for advanced EGFR-mutated NSCLC: a meta-analysis of randomized phase III trialsThierry Landre, Jean-Baptiste Assié, Kader Chouahnia, et al.Expert Review of Anticancer Therapy|May 18, 2024
Risk-stratification for treatment de-intensification in WNT-pathway medulloblastoma: finding the optimal balance between survival and quality of survivorshipTejpal Gupta, Shakthivel Mani, Abhishek Chatterjee, et al.Expert Review of Anticancer Therapy|May 7, 2024
Is there a link between talcum powder, oxidative stress, and ovarian cancer risk?Ghassan M SaedExpert Review of Anticancer Therapy|May 1, 2024
Efficacy and safety of neoadjuvant therapy for HR-positive/HER2-negative early breast cancer: a Bayesian network meta-analysisRuiliang Chen, Yushuai Yu, Jie Zhang, et al.Pageof 311